文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

头盔式与面罩式持续气道正压治疗急诊急性呼吸衰竭的随机临床试验

Randomized clinical trial comparing helmet continuous positive airway pressure (hCPAP) to facemask continuous positive airway pressure (fCPAP) for the treatment of acute respiratory failure in the emergency department.
PubMed 文献 · Am J Emerg Med · 2021-06-22
一句话结论在急诊急性心源性肺水肿或COPD失代偿患者中,头盔CPAP在降低呼吸频率方面不劣于面罩CPAP,且舒适度更高、插管率更低。

该非劣效随机临床试验在急诊科纳入224例急性呼吸衰竭患者,随机分为头盔CPAP组(113例)和面罩CPAP组(111例)。主要终点为呼吸频率下降,两种方式均有效降低呼吸频率、心率,改善呼吸困难和动脉氧合。头盔CPAP组插管率显著低于面罩CPAP组(4.4% vs 18%,绝对差-13.6%,p=0.003),且不适感和黏膜干燥更少。结论提示在急诊急性心源性肺水肿或COPD失代偿患者中,头盔CPAP不劣于面罩CPAP且耐受性更好。

要点

  • 在急诊急性心源性肺水肿或COPD失代偿患者中,头盔CPAP插管率4.4%,面罩CPAP为18%,绝对差-13.6%(p=0.003)。
  • 头盔CPAP组呼吸频率从33.56±3.07降至25.43±3.11次/分,面罩CPAP组从33.46±3.35降至27.01±3.19次/分。
  • 头盔CPAP组不适感和黏膜干燥均低于面罩CPAP组。
  • 两种CPAP方式均改善PaO2和PaO2:FiO2比值,头盔CPAP组PaO2:FiO2从113.6±13.4升至273.4±49.5,面罩组从115.0±12.9升至307.7±60.9。
  • 头盔CPAP在急诊急性呼吸衰竭患者中可作为面罩CPAP的替代选择,尤其考虑舒适度和插管风险时。

适用人群与场景

  • 急诊科就诊的急性呼吸衰竭患者,包括急性心源性肺水肿或COPD失代偿者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 根据试验方案随机分配接受头盔CPAP或面罩CPAP治疗。
  • 原文未提及具体CPAP压力设置、给药频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 非劣效随机临床试验,单中心,纳入224例急诊急性呼吸衰竭患者,随机分为头盔CPAP组(113例)和面罩CPAP组(111例)。
  • 主要终点呼吸频率下降:头盔CPAP组从33.56±3.07降至25.43±3.11次/分,面罩CPAP组从33.46±3.35降至27.01±3.19次/分。
  • 插管率:头盔CPAP组4.4%,面罩CPAP组18%,绝对差-13.6%(p=0.003)。
  • 头盔CPAP组不适感和黏膜干燥更低;两组均改善呼吸困难(VAS和Likert量表)、心率、PaO2和PaO2:FiO2。

证据类型、等级与局限

  • 证据类型:非劣效随机临床试验(RCT)。
  • 局限:单中心研究;原文未提及盲法、样本量计算细节或非劣效界值。

对床旁实践的改变

  • 在急诊急性心源性肺水肿或COPD失代偿的急性呼吸衰竭患者中,头盔CPAP可作为面罩CPAP的替代,可能降低插管率并提高舒适度。
  • 原文未提及适用或不适用人群的进一步限制,临床决策需结合患者具体情况。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

STUDY OBJECTIVE: To determine whether non-invasive ventilation (NIV) delivered by helmet continuous positive airway pressure (hCPAP) is non-inferior to facemask continuous positive airway pressure (fCPAP) in patients with acute respiratory failure in the emergency department (ED).

METHODS: Non-inferiority randomized, clinical trial involving patients presenting with acute respiratory failure conducted in the ED of a local hospital. Participants were randomly allocated to receive either hCPAP or fCPAP as per the trial protocol. The primary endpoint was respiratory rate reduction. Secondary endpoints included discomfort, improvement in Dyspnea and Likert scales, heart rate reduction, arterial blood oxygenation, partial pressure of carbon dioxide (PaCO2), dryness of mucosa and intubation rate.

RESULTS: 224 patients were included and randomized (113 patients to hCPAP, 111 to fCPAP). Both techniques reduced respiratory rate (hCPAP: from 33.56 ± 3.07 to 25.43 ± 3.11 bpm and fCPAP: from 33.46 ± 3.35 to 27.01 ± 3.19 bpm), heart rate (hCPAP: from 114.76 ± 15.5 to 96.17 ± 16.50 bpm and fCPAP: from 115.07 ± 14.13 to 101.19 ± 16.92 bpm), and improved dyspnea measured by both the Visual Analogue Scale (hCPAP: from 16.36 ± 12.13 to 83.72 ± 12.91 and fCPAP: from 16.01 ± 11.76 to 76.62 ± 13.91) and the Likert scale. Both CPAP techniques improved arterial oxygenation (PaO2 from 67.72 ± 8.06 mmHg to 166.38 ± 30.17 mmHg in hCPAP and 68.99 ± 7.68 mmHg to 184.49 ± 36.38 mmHg in fCPAP) and the PaO2:FiO2 (Partial pressure of arterial oxygen: Fraction of inspired oxygen) ratio from 113.6 ± 13.4 to 273.4 ± 49.5 in hCPAP and 115.0 ± 12.9 to 307.7 ± 60.9 in fCPAP. The intubation rate was lower with hCPAP (4.4% for hCPAP versus 18% for fCPAP, absolute difference -13.6%, p = 0.003). Discomfort and dryness of mucosa were also lower with hCPAP.

CONCLUSION: In patients presenting to the ED with acute cardiogenic pulmonary edema or decompensated COPD, hCPAP was non-inferior to fCPAP and resulted in greater comfort levels and lower intubation rate.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Adi O, Via G, Salleh SH, et al. Randomized clinical trial comparing helmet continuous positive airway pressure (hCPAP) to facemask continuous positive airway pressure (fCPAP) for the treatment of acute respiratory failure in the emergency department. Am J Emerg Med. 2021. PMID: 34271286. doi:10.1016/j.ajem.2021.06.031

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。